By Professor Richard Bryan Lock

Preprints

Truong P; Shen S; Joshi S; Islam MI; Zhong L; Raftery MJ; Afrasiabi A; Alinejad-Rokny H; Nguyen M; Zou X; Bhuyan GS; Sarowar CH; Ghodousi ES; Stonehouse O; Mohamed S; Toscan CE; Connerty P; Kakadia PM; Bohlander SK; Michie KA; Larsson J; Lock RB; Walkley CR; Thoms JAI; Jolly CJ; Pimanda JE, 2024, Genome-Wide CRISPR-Cas9 Screening Identifies a Synergy between Hypomethylating Agents and SUMOylation Blockade in MDS/AML, http://dx.doi.org/10.1101/2024.04.17.589858

Tremblay C; Saw J; Yan F; Boyle J; Amarasinghe O; Abdollahi S; Vo NQA; Shields B; Mayoh C; McCalmont H; Evans K; Steiner A; Parsons K; McCormack M; Powell D; Wong N; Jane S; Lock R; Curtis D, 2024, Targeting LMO2-induced autocrine FLT3 signalling to overcome chemoresistance in early T-cell precursor acute lymphoblastic leukemia, http://dx.doi.org/10.21203/rs.3.rs-4608404/v1

Fordham A; Brown L; Mayoh C; Salib A; Barger Z; Wong M; Sian TCCLK; Xie J; Gunther K; Trebilcock P; Terry R; Barahona P; Ajuyah P; Sherstyuk A; Avila A; Cadiz R; Perkins C; Gifford A; Mao J; Zhao A; O’Regan L; Gorgels D; Lau LMS; Ziegler D; Haber M; Tyrrell V; Lock R; Cowley M; Nicholls W; Daly R; Ekert P; Fleuren EDG, 2023, Comprehensive multi-platform tyrosine kinase profiling reveals novel actionable FGFR aberrations across pediatric and AYA sarcomas, http://dx.doi.org/10.1101/2023.07.19.548825

Ziegler D; Lau L; Khuong-Quang D-A; Mayoh C; Wong M; Barahona P; Ajuyah P; Senapati A; Nagabushan S; Sherstyuk A; Altekoester A-K; Fuentes-Bolanos N; Yeung V; Sullivan A; Diamond Y; Omer N; Jessop S; Battaglia L; Zhukova N; Cui L; Lin A; Gifford A; Fleuren E; Dalla-Pozza L; Moore A; Khaw S; Eisenstat D; Gottardo N; Wood P; Tapp H; Alvaro F; McCowage G; Nicholls W; Hansford J; Manoharan N; Kotecha R; Mateos M; Lock R; Tyrrell V; Haber M; Trahair T; Cowley M; Ekert P; Marshall G, 2023, Precision-guided treatment improves outcomes for children with high-risk cancers, http://dx.doi.org/10.21203/rs.3.rs-3376668/v1

Germon Z; Sillar J; Mannan A; Duchatel R; Staudt D; Murray H; Findlay I; Jackson E; McEwen H; Douglas A; McLachlan T; Schjenken J; Skerrett-Bryne D; Huang H; Melo-Braga M; Plank M; Alvaro F; Chamberlain J; Iuliis GD; Aitken J; Nixon B; Wei A; Enjeti A; Lock R; Larsen M; Lee H; de Bock C; Verrills N; Dun M, 2022, Blockade of redox second messengers inhibits JAK/STAT and MEK/ERK signaling sensitizing FLT3-mutant acute myeloid leukemia to targeted therapies, http://dx.doi.org/10.1101/2022.03.09.483687

Rokita JL; Rathi K; Cardenas M; Upton K; Jayaseelan J; Cross K; Pfeil J; Ritenour L; Modi A; Farrel A; Way G; Kendsersky N; Patel K; Lopez G; Vaksman Z; Mayoh C; Nance J; McCoy K; Haber M; Evans K; McCalmont H; Bendak K; Böhm J; Marshall G; Tyrrell V; Kalletla K; Braun F; Qi L; Du Y; Zhang H; Lindsay H; Zhao S; Shu J; Baxter P; Morton C; Kurmashev D; Zheng S; Chen Y; Bowen J; Bryan A; Leraas K; Coppens S; Doddapaneni H; Momin Z; Zhang W; Sacks G; Hart L; Krytska K; Mosse Y; Gatto G; Sanchez Y; Greene C; Diskin S; Vaske OM; Haussler D; Gastier-Foster J; Kolb A; Gorlick R; Li X-N; Reynolds P; Kurmasheva R; Houghton P; Smith M; Lock R; Raman P; Wheeler D; Maris J, 2019, Genomic profiling of childhood tumor patient-derived xenograft models to enable rational clinical trial design, http://dx.doi.org/10.1101/566455

Rokita JL; Rathi KS; Cardenas MF; Upton KA; Jayaseelan J; Cross KL; Pfeil J; Ritenour LE; Modi A; Farrel A; Way GP; Kendsersky NM; Patel K; Lopez G; Vaksman Z; Mayoh C; Nance J; Mccoy K; Haber M; Evans K; McCalmont H; Bendak K; Böhm JW; Marshall GM; Tyrrell V; Kalletla K; Braun FK; Qi L; Du Y; Zhang H; Lindsay HB; Zhao S; Shu J; Baxter P; Morton C; Kurmashev D; Zheng S; Chen Y; Bowen J; Bryan AC; Leraas KM; Coppens SE; Doddapaneni H; Momin Z; Zhang W; Sacks GI; Hart LS; Krytska K; Mosse YP; Gatto GJ; Sanchez Y; Greene CS; Diskin SJ; Morozova Vaske O; Haussler D; Gastier-Foster JM; Kolb EA; Gorlick R; Li X-N; Reynolds CP; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB; Raman P; Wheeler DA; Maris JM, Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design, http://dx.doi.org/10.2139/ssrn.3377367

Wakefield C; Doolan EL; Fardell JE; Signorelli C; Veronica QF; Tucker KM; Patenaude AF; Marshall GM; Lock RB; Georgiou G; Cohn RJ, The Avatar Acceptability Study: Survivor, Parent and Community Willingness to Use Patient-Derived Xenografts to Personalize Cancer Care, http://dx.doi.org/10.2139/ssrn.3260779

Back to profile page